Contribute Try STAT+ Today

WASHINGTON — A key Senate panel is seriously considering a new policy that would soften the blow of drug pricing reform for small biotech companies, according to two sources familiar with the talks. But the concession isn’t likely to win over the biotech industry.

The change would be part of a package of broader drug pricing reforms from Senate Finance Committee Chairman Ron Wyden (D-Ore.), who promised, vaguely, to protect the smaller companies earlier this year. But the specifics of his policy have been unclear until now, as Democrats in both chambers of Congress look to include some kind of drug pricing reform in the massive government spending bill they’re debating in earnest.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment